Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD)
$0.31
+0.0052 ( +1.71% ) 87.9K
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Market Data
Open
$0.31
Previous close
$0.31
Volume
87.9K
Market cap
$1.91M
Day range
$0.30 - $0.32
52 week range
$0.26 - $1.50
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 1 | Jul 11, 2024 |
6-k | Quarterly Reports | 4 | Jun 05, 2024 |
6-k | Quarterly Reports | 1 | May 30, 2024 |
20-f | Annual reports | 87 | Apr 04, 2024 |
6-k | Quarterly Reports | 1 | Mar 19, 2024 |
6-k | Quarterly Reports | 2 | Mar 15, 2024 |
6-k | Quarterly Reports | 1 | Nov 22, 2023 |
6-k | Quarterly Reports | 2 | Nov 20, 2023 |
6-k | Quarterly Reports | 3 | Sep 26, 2023 |
6-k | Quarterly Reports | 3 | Sep 22, 2023 |